Oniki S - Search Results

1

In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.

Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M, Nishigori C, Ichihashi M. Nagai H, et al. Among authors: oniki s. Exp Dermatol. 2004 Oct;13(10):613-20. doi: 10.1111/j.0906-6705.2004.00198.x. Exp Dermatol. 2004. PMID: 15447721

2

Engagement of CD47 inhibits the contact hypersensitivity response via the suppression of motility and B7 expression by Langerhans cells.

Yu X, Fukunaga A, Nagai H, Oniki S, Honma N, Ichihashi M, Matozaki T, Nishigori C, Horikawa T. Yu X, et al. Among authors: oniki s. J Invest Dermatol. 2006 Apr;126(4):797-807. doi: 10.1038/sj.jid.5700176. J Invest Dermatol. 2006. PMID: 16456531 Free article.

3

Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.

Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C. Oniki S, et al. Cancer Res. 2006 Jun 15;66(12):6395-404. doi: 10.1158/0008-5472.CAN-05-4087. Cancer Res. 2006. PMID: 16778218

4

Induction of cellular immunity against hair follicle melanocyte causes alopecia.

Nagai H, Oniki S, Oka M, Horikawa T, Nishigori C. Nagai H, et al. Among authors: oniki s. Arch Dermatol Res. 2006 Aug;298(3):131-4. doi: 10.1007/s00403-006-0668-y. Epub 2006 Jun 20. Arch Dermatol Res. 2006. PMID: 16786344

5

Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response.

Furukawa J, Hara I, Nagai H, Yao A, Oniki S, Fujisawa M. Furukawa J, et al. Among authors: oniki s. J Urol. 2006 Sep;176(3):1198-203. doi: 10.1016/j.juro.2006.04.037. J Urol. 2006. PMID: 16890725

6

Antitumor activities of interleukin-27 on melanoma.

Nagai H, Oniki S, Fujiwara S, Xu M, Mizoguchi I, Yoshimoto T, Nishigori C. Nagai H, et al. Among authors: oniki s. Endocr Metab Immune Disord Drug Targets. 2010 Mar;10(1):41-6. doi: 10.2174/187153010790827920. Endocr Metab Immune Disord Drug Targets. 2010. PMID: 19845503 Review.

7

Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Fujiwara S, Nagai H, Shimoura N, Oniki S, Yoshimoto T, Nishigori C. Fujiwara S, et al. Among authors: oniki s. J Invest Dermatol. 2014 Jul;134(7):1884-1892. doi: 10.1038/jid.2014.42. Epub 2014 Jan 27. J Invest Dermatol. 2014. PMID: 24468748 Free article.

8

Src homology 2 domain-containing protein tyrosine phosphatase substrate 1 regulates the induction of Langerhans cell maturation.

Fukunaga A, Nagai H, Yu X, Oniki S, Okazawa H, Motegi S, Suzuki R, Honma N, Matozaki T, Nishigori C, Horikawa T. Fukunaga A, et al. Among authors: oniki s. Eur J Immunol. 2006 Dec;36(12):3216-26. doi: 10.1002/eji.200635864. Eur J Immunol. 2006. PMID: 17109464 Free article.

9

Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.

Kumano M, Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M. Kumano M, et al. Among authors: oniki s. J Urol. 2007 Oct;178(4 Pt 1):1504-9. doi: 10.1016/j.juro.2007.05.115. Epub 2007 Aug 16. J Urol. 2007. PMID: 17707061

10

Antiproliferative activity of IL-27 on melanoma.

Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J. Yoshimoto T, et al. Among authors: oniki s. J Immunol. 2008 May 15;180(10):6527-35. doi: 10.4049/jimmunol.180.10.6527. J Immunol. 2008. PMID: 18453571

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters